Canadian Government Executive - Volume 26 - Issue 03

May/June 2020 // Canadian Government Executive / 9 Figure 1. Relationship between Curaizon™ Components TECHNOLOGY Methodology: An AI Approach Any solution that seeks to address non-adher- ence needs to be scal- able, dynamic, low cost and flexible. The Curaizon™ solu- tion, now available, is a patient-centric, interactive and technology-driven one. The strength of this solution is the real-time data reporting and advanced data analyt- ics and AI techniques that provide valu- able patient insights that empower medi- cal professionals to be proactive rather than reactive. Here’s how it works: Once patients are prescribed a medication, with the pa- tient’s permission, the doctor enrolls them in CuraServe™. The enrollment enables the patients to receive reminders to take their medications, and when they do, they record it, which is captured in CuraData™. A unique feature of CuraServe™ is that it has a built-in safety net and can escalate non-adherence by notifying the patient’s family member or healthcare professional should the patient fail to take their medi- cation. The healthcare provider, doctors and patients can see all their own records in CuraView™. It entails three major com- ponents described in Figure 1. A key feature of this Big Data and AI system is its ability to yield key indicators that can support contribution and attribu- tion outcomes [2]. Conclusion “If adherence therapy were a new drug, it would be hailed as a potentially major ad- vance in medical treatment.” — Professor Richard Gray. There is no doubt that the spiralling costs of healthcare need to be checked and that finite resources must be used efficiently if we are to continue provid- ing leading healthcare to the population while maintaining budgets. By engaging with advanced data analyt- ics and AI, healthcare providers can de- liver scalable and cost-effective solutions that will dramatically improve patient outcomes, while reducing the avoidable waste that occurs as a result of low adher- ence to medications. The scale of the chal- lenge before us is now matched by the technological advances necessary to affect real change. References 1. Glenn Monteith. (2018). Canada’s artificial-in- telligence advantage in healthcare. Opinions. Downloaded from the internet on January 8, 2020. https://ipolitics.ca/2018/08/29/ canadas-artificial-intelligence-advantage-in- healthcare/ 2. This paper defines adherence as: “The extent to which the patient’s behaviour matches agreed recommendations from the pre- scriber.” 3. The AI solution focus herein leads to both contribution and attrition outcome manage- ment based on a theory of change. 4. Curaizon™ does not guarantee and does not accept legal responsibility of any nature, for any indirect, special, incidental, consequen- tial or other losses of any kind, in short, contract or otherwise (including but not limited to loss of revenue, income or profits, and loss of use or data), arising from or related to the accuracy, reliability, relevance or completeness of any material 5. Centers for Disease Control and Prevention, Centers for Disease Control and Preven- tion. (2019). Health and Economic Costs of Chronic Diseases. Retrieved from https:// www.cdc.gov/chronicdisease/about/costs/ index.htm. 6. Lau DT, Nau DP. (2004). Oral antihypergly- cemic medication nonadherence and sub- sequent hospitalization among individuals with type 2 diabetes. Diabetes Care. 27(9): 2149-2153. 7. Gupta, S. et al. (2018). Cost-related non- adherence to prescription medications in Canada: a scoping review. Dover Press, Patient Preference and Adherence. Volume 12, 16 May. 8. Sequist, Thomas D , et al. (2005). A Ran- domized Trial of Electronic Clinical Remind- ers to Improve Quality of Care for Diabetes and Coronary Artery Disease .Journal of the American Medical Informatics Associa- tion, Volume 12, Issue 4, July, Pages 431–437, https://doi.org/10.1197/jamia.M1788. 9. Montague, T.; Manness, Lori-Jean; Cochrane, Bonnie; Gogovor, Amédé ; Aylen, John; Mar- tin, Lesli; and Nemis-White, Joanna. (2017). Non-adherence to Prescribed Therapy: A Persistent Contributor to the Care Gap. HCIC. 10. This represents the number of patients in more than 40 countries covered by national health services around the globe. 11. Kenneth, D.; Murphy, S.L.; Anderson, R.N.; and Scott C. (2002). National Vital Statistics Reports. Center for Disease Control: Division of Vital Statistics. Volume 53, Number 5. 12. Centers for Disease Control and Preven- tion. (2019). Health and Economic Costs of Chronic Diseases. Downloaded from the in- ternet .https://www.cdc.gov/chronicdisease/ about/costs/index.htm. 13. Law, MR; et al (2012). The effect of cost on adherence to prescription medications in Canada. Canadian Medical Association Jour- nal. 184(3): 297-302. 14. Curaizon™ does not guarantee and does not accept legal responsibility of any nature, for any indirect, special, incidental, conse- quential or other losses of any kind, in short, contract or otherwise (including but not limited to loss of revenue, income or profits, and loss of use or data), arising from or related to the accuracy, reliability, relevance or completeness of any material 15. Health Canada. (2019). A Prescription for Canada: Achieving Pharmacare for All. Final Report of the Advisory Council on the Imple- mentation of National Pharmacare. ISBN: 978-0-660-30974-3 16. Centers for Disease Control and Prevention, Centers for Disease Control and Preven- tion. (2017). Chronic Disease Prevention and Health Promotion. 28 June. 17. Jeff, L. (2018). 5 Frightening Stats on Medi- cation Adherence (plus Infographic). Philly Digest. May 16. 18. IJ Staff (2019). Majority of Canadians do not take their medication as prescribed. Insurance Portal. April 30. Downloaded from the internet May 21, 2020. https://insurance- portal.ca/article/majority-of-canadians-do- not-take-their-medication-as-prescribed/ Nicholas James Rumble is the founder and CEO of Curaizon and has a back- ground in mathematics, economics and data. He has spent much of his working life inside investment banking, where he was instrumental in pioneering new trading technologies. He brings more than 20 years of business experience and knows how to bring teams of great people together and execute high-level plans; especially where technology plays a key role. Betty Ann M. Turpin, President of Turpin Consultants Inc., is a manage- ment consultant who has also worked in the federal government. Her career focus is performance measurement, data analytics, evaluation, and research. She is a Board Advisor on, and Canadian representative for, Curaizon. Jack Bryant has spent his professional career in institutional sales and rela- tionship management in the financial services and advertising industries in Boston and the San Francisco Bay Area. His passion is helping businesses efficiently grow while leveraging tech- nology and key account management techniques.